NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction
NCT02990338: Phase 3 - Isatuximab, Pomalidomide & Dex VS Pom & Dex in relapsed Myeloma (ICARIA-MM)
NCT02728102: Phase 2 - Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
NCT02655458: Phase 1 - Elotuzumab in Comb. With Auto transplant and Lenalidomide Maintenance in MM
NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
NCT02884102: MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation
NCT02833610: Phase 2 - A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
NCT02693535: Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs
Myeloma Canada: Patient Handbook - Myeloma and the Kidney
International Myeloma Working Group Recs for Diagnosis & Manag. of Myeloma-Related Renal Impairment
FDA Approved for RRMM: Daratumumab + Revlimid & Dex AND Daratumumab + Velcade & Dex
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma